Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNNNN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAnbio Biotechnology
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 19, 2025
āļāļĩāļāļĩāđāļLau (Michael)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ27
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 19
āļāļĩāđāļāļĒāļđāđFriedrich-Ebert-Anlage 49
āđāļĄāļ·āļāļFRANKFURT AM MAIN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻGermany
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ60308
āđāļāļĢāļĻāļąāļāļāđ4916096247281
āđāļ§āđāļāđāļāļāđhttps://anbiobiotechnology.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNNNN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 19, 2025
āļāļĩāļāļĩāđāļLau (Michael)
Mr. Michael Lau
Chief Executive Officer
Ms. Suki Song
Chief Financial Officer
Mr. Chris Tiantian
Chief Business Officer
Mr. Cany Xu
Executive Director
Ms. Nancy Hartzler
Independent Director
Mr. David Hsu
Independent Director
Mr. Michael Zhang
Independent Director
Mr. Michael Lau
Chief Executive Officer
Ms. Suki Song
Chief Financial Officer
Mr. Chris Tiantian
Chief Business Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Michael Lau
Chief Executive Officer
Ms. Suki Song
Chief Financial Officer
Mr. Chris Tiantian
Chief Business Officer
Mr. Cany Xu
Executive Director
Ms. Nancy Hartzler
Independent Director
Mr. David Hsu
Independent Director